As with any GLP-1 medication, side effects such as nausea, fatigue, and gastrointestinal discomfort are possible
Mechanism of Action IGF-1 LR3 is studied for its interaction with the insulin-like growth factor 1 receptor (IGF1R), a transmembrane receptor involved in intracellular signaling cascades
Common approaches: Healing peptides: BPC-157 and TB-500 are often run for 6-12 week cycles, with 2-4 week breaks between
Key contraindications and poor candidate scenarios include: Men with significant cardiovascular disease or uncontrolled hypertension as mentioned, the transient BP increase is not suitable for those with serious heart conditions
In terms of renal protection, semaglutide has the strongest data, with a dedicated renal outcomes trial
"Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide." Journal of Women's Health